Cornerstone Pharmaceuticals is a renowned brand dedicated to developing innovative cancer therapies that target the most challenging forms of the disease. They focus on treating cancers such as AML, Burkitt's lymphoma, and pancreatic cancer. With a strong emphasis on research and development, Cornerstone has created CPI-613® (devimistat), their lead compound.

This unique therapy disrupts the energy production of cancer cells by targeting their mitochondria, effectively cutting off the fuel for disease growth. CPI-613® has been granted orphan drug designation by the FDA for indications including Burkitt's lymphoma and biliary tract cancer. Cornerstone's commitment extends to rare cancers with limited treatment options, striving to improve the lives of patients in a compassionate manner.

With a world-class team of industry experts and esteemed advisors, Cornerstone Pharmaceuticals is on a mission to transform cancer treatment and bring hope to those in need